PMV Pharmaceuticals, Inc. (PMVP)

US — Healthcare Sector
Peers: ELYM  MNOV  PHVS  PEPG  ANEB  ACRV  MOLN  MLYS  EWTX  RLYB  OPT  GLUE  TRDA  VIGL 

Automate Your Wheel Strategy on PMVP

With Tiblio's Option Bot, you can configure your own wheel strategy including PMVP - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PMVP
  • Rev/Share 0.0
  • Book/Share 3.0818
  • PB 0.2905
  • Debt/Equity 0.0069
  • CurrentRatio 16.7537
  • ROIC -0.4235

 

  • MktCap 46518448.0
  • FreeCF/Share -1.0284
  • PFCF -0.8707
  • PE -0.7642
  • Debt/Assets 0.0065
  • DivYield 0
  • ROE -0.3254

 

  • Rating B-
  • Score 3
  • Recommendation Neutral
  • P/E Score 1
  • DCF Score 4
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMVP
Published: March 05, 2025 by: Zacks Investment Research
Sentiment: Neutral

PMV Pharmaceuticals (PMVP) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Read More
image for news Here's Why PMV Pharmaceuticals (PMVP) Looks Ripe for Bottom Fishing
PMV Pharmaceuticals to Participate at Upcoming Investor Conferences
PMVP
Published: February 11, 2025 by: GlobeNewsWire
Sentiment: Neutral

PRINCETON, N.J., Feb. 11, 2025 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that David H. Mack, Ph.D., President and Chief Executive Officer and Deepika Jalota, Pharm. D., Chief Development Officer, will participate at the following investor conferences. Management will also participate in one-on-one investor meetings.

Read More
image for news PMV Pharmaceuticals to Participate at Upcoming Investor Conferences

About PMV Pharmaceuticals, Inc. (PMVP)

  • IPO Date 2020-09-25
  • Website https://www.pmvpharma.com
  • Industry Biotechnology
  • CEO Dr. David H. Mack Ph.D.
  • Employees 47
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.